At the six-month follow-up, approximately 40% of patients treated with evenamide experienced substantial symptomatic improvement—so much so that they no longer satisfied the original entry criteria into the study with their disease no longer meeting the qualification for treatment resistance, according to Newron.
3 Likes
lol. The title totally sounds like someone is competing in a tournament to win schizophrenia as a prize.
Sounds like good news with people that have treatment resistant sz.
1 Like
Evenamide (30 mg bid) is also under evaluation as a treatment for patients with chronic schizophrenia in study 008A —a 4-week, randomized, double-blind, placebo-controlled study. Full results from study 008A are expected to be released in late 2023 or early 2024.
2 Likes